FI960850A - Användning av kinoxaliner i kombination med proteasinhibitorer som läkemedel vid behandling av AIDS och/eller HIV-infektioner - Google Patents

Användning av kinoxaliner i kombination med proteasinhibitorer som läkemedel vid behandling av AIDS och/eller HIV-infektioner Download PDF

Info

Publication number
FI960850A
FI960850A FI960850A FI960850A FI960850A FI 960850 A FI960850 A FI 960850A FI 960850 A FI960850 A FI 960850A FI 960850 A FI960850 A FI 960850A FI 960850 A FI960850 A FI 960850A
Authority
FI
Finland
Prior art keywords
quinoxalins
aids
drugs
treatment
combination
Prior art date
Application number
FI960850A
Other languages
English (en)
Finnish (fi)
Other versions
FI960850A0 (sv
Inventor
Arnold Paessens
Martin Blunck
Guenther Riess
Joerg-Peter Kleim
Manfred Roesner
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI960850A0 publication Critical patent/FI960850A0/sv
Publication of FI960850A publication Critical patent/FI960850A/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI960850A 1995-02-27 1996-02-23 Användning av kinoxaliner i kombination med proteasinhibitorer som läkemedel vid behandling av AIDS och/eller HIV-infektioner FI960850A (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19506742A DE19506742A1 (de) 1995-02-27 1995-02-27 Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen

Publications (2)

Publication Number Publication Date
FI960850A0 FI960850A0 (sv) 1996-02-23
FI960850A true FI960850A (sv) 1996-08-28

Family

ID=7755115

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960850A FI960850A (sv) 1995-02-27 1996-02-23 Användning av kinoxaliner i kombination med proteasinhibitorer som läkemedel vid behandling av AIDS och/eller HIV-infektioner

Country Status (19)

Country Link
EP (1) EP0728481A3 (sv)
JP (1) JPH08245392A (sv)
KR (1) KR960030951A (sv)
CN (1) CN1141196A (sv)
AR (1) AR003923A1 (sv)
AU (1) AU710158B2 (sv)
BR (1) BR9600809A (sv)
CA (1) CA2170222A1 (sv)
CZ (1) CZ57896A3 (sv)
DE (1) DE19506742A1 (sv)
FI (1) FI960850A (sv)
HR (1) HRP960070A2 (sv)
HU (1) HUP9600455A3 (sv)
IL (1) IL117247A (sv)
NO (1) NO960775L (sv)
NZ (1) NZ286058A (sv)
PL (1) PL312908A1 (sv)
SK (1) SK25196A3 (sv)
ZA (1) ZA961516B (sv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716760B2 (en) * 1996-11-08 2000-03-09 Japan Energy Corporation Aids therapeutic composition
DE19703131A1 (de) * 1997-01-29 1998-07-30 Bayer Ag Verwendung von Chinoxalin in Dreier-Kombination mit Protease-Inhibitoren und Reverse Transkriptaseinhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
DE69940808D1 (de) * 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
GB9911887D0 (en) * 1999-05-21 1999-07-21 Glaxo Group Ltd Methods and medicaments for post exposure prophylaxis of an hiv infection
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
JP4206382B2 (ja) 2002-11-19 2009-01-07 アキリオン ファーマシューティカルズ，インコーポレーテッド 置換されたアリールチオウレアおよび関連化合物；ウイルス複製のインヒビター
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
EP2935260A1 (de) * 2012-12-20 2015-10-28 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydropyridopyrazinone
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59209965D1 (de) * 1991-04-15 2002-10-17 Aventis Pharma Gmbh Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
FI960850A0 (sv) 1996-02-23
HUP9600455A3 (en) 1998-04-28
CN1141196A (zh) 1997-01-29
EP0728481A3 (de) 1998-07-08
BR9600809A (pt) 1997-12-23
AU4561596A (en) 1996-09-05
EP0728481A2 (de) 1996-08-28
CZ57896A3 (en) 1996-09-11
NO960775D0 (no) 1996-02-26
AU710158B2 (en) 1999-09-16
NZ286058A (en) 1998-09-24
HU9600455D0 (en) 1996-04-29
DE19506742A1 (de) 1996-08-29
PL312908A1 (en) 1996-09-02
ZA961516B (en) 1996-09-03
CA2170222A1 (en) 1996-08-28
HRP960070A2 (en) 1997-10-31
NO960775L (no) 1996-08-28
HUP9600455A2 (en) 1996-12-30
IL117247A (en) 2000-10-31
SK25196A3 (en) 1997-05-07
JPH08245392A (ja) 1996-09-24
IL117247A0 (en) 1996-06-18
AR003923A1 (es) 1998-09-30
KR960030951A (ko) 1996-09-17

Similar Documents

Publication Publication Date Title
FI955315A0 (sv) Inhibitorer av HIV proteas, som användbara vid behandling av AIDS
FI960850A (sv) Användning av kinoxaliner i kombination med proteasinhibitorer som läkemedel vid behandling av AIDS och/eller HIV-infektioner
FI970357A0 (sv) Bensoxazol- och pyridinderivat användbara vid behandling av diabetes av typ II
DK0956858T3 (da) Farmaceutiske præparater indeholdende lactobacilli til behandling af vaginale infektioner
BR9406209A (pt) Derivados heterociclicos no tratamento de isquemia e doenças relacionadas
ITBO910476A0 (it) -formulazioni farmeceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali.
MX9202839A (es) 4-aminoquinolinas y composiciones farmaceuticas de las mismas.
DK1181027T3 (da) Diætetisk eller farmaceutisk præparat til anvendelse til forebyggelsen eller behandling af hyperoxaluri
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
FI963883A (sv) Farmaceutiska preparat och läkemedel för förhindrande och behandling av funktionsstörningar i endotelen
EE200200271A (et) Ravimkombinatsioonid ning nende kasutamine
ID22414A (id) Penggunaan kuinoksalina dalam suatu kombinasi tripel dengan penghambat protease dan penghambat transkriptase balik sebagai obat untuk pengobatan aids dan/atau infeksi hiv
PL366855A1 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
TR200401363T4 (tr) DNA viral enfeksiyonlarının tedavisi
FI935780A (sv) HIV-proteasinhibitorer, vilka aer anvaendbara vid behandling av AIDS
NO940810D0 (no) Behandling av virusinfeksjoner
ITRM930286A0 (it) Composizione farmaceutica per somministrazione rettale nel trattamentodi cefaleo e relativo metodo di preparazione ed impiego.
FI954964A (sv) Användande av vWF-haltiga koncentrat som kombinationsterapi vid terapi med antitrombotika och fibrinolytika
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
DE60034770D1 (de) Stabile fumagillin-formulierung
FI952018A0 (sv) Användning av BHAP-föreningar i kombination med andra icke-nukeocid-transverstransskriptasinhibitorer för behandling av HIV-infektion
FI941707A0 (sv) Användning av naftokinoner vid behandling och profylax av P. carinii -infektioner
FI972637A0 (sv) Användning av K-gruppens vitamin vid behandling av hyperparatyreoidism
FR2702151B1 (fr) Application d'anticonvulsivants dans le traitement du neuro-sida.